Annual Report • May 28, 2025
Annual Report
Open in ViewerOpens in native device viewer
May–April 2024/25

| Q4 | Full year | |||||
|---|---|---|---|---|---|---|
| SEK M | 2024/25 | 2023/24 | Δ | 2024/25 | 2023/24 | Δ |
| Book-to-bill | 1.12 | 1.28 | -12% | 1.09 | 1.09 | 1% |
| Net sales | 5,156 | 5,023 | 3% | 18,016 | 18,119 | -1% |
| Net sales in constant exchange rates | 6% 1 | 1% | ||||
| Adjusted gross margin 2 | 40.3% | 36.6% | 3.7 ppts | 37.8% | 37.5% | 0.3 ppts |
| Adjusted EBITDA 3 | 1,165 | 956 | 22% | 3,396 | 3,287 | 3% |
| Adjusted EBITDA margin 3 | 22.6% | 19.0% | 3.6 ppts | 18.8% | 18.1% | 0.7 ppts |
| Adjusted EBIT 4 | 843 | 651 | 29% | 2,097 | 2,145 | -2% |
| Adjusted EBIT margin 4 | 16.3% | 13.0% | 3.4 ppts | 11.6% | 11.8% -0.2 ppts | |
| Gross margin | 39.8% | 36.4% | 3.4 ppts | 37.4% | 37.4% | 0 ppts |
| EBITDA | 1,189 | 930 | 28% | 3,283 | 3,189 | 3% |
| EBITDA margin | 23.1% | 18.5% | 4.5 ppts | 18.2% | 17.6% | 0.6 ppts |
| EBIT | -197 | 617 | -132% | 890 | 2,039 | -56% |
| EBIT margin | -3.8% | 12.3% -16.1 ppts | 4.9% | 11.3% -6.3 ppts | ||
| Net income | -381 | 414 | -192% | 240 | 1,302 | -82% |
| Cash flow after continuous investments |
1,248 | 872 | 376 | 1,056 | 815 | 241 |
| Adjusted earnings per share before/after dilution, SEK 5 | 1.11 / 1.11 1.15 / 1.15 | -4% | 3.08 / 3.08 3.62 / 3.62 | -15% | ||
| Earnings per share before/after dilution, SEK | -1.01 / -1.01 1.08 / 1.08 | -193% | 0.62 / 0.62 3.41 / 3.41 | -82% | ||
| 1 Compared to last fiscal year based on constant exchange rates. 2 Adjusted gross margin = Gross margin excluding items affecting comparability attributable to the Cost-reduction Initiative and the R&D impairment cost., see page 28. 3 Adjusted EBITDA = EBITDA excluding items affecting comparability attributable to the Cost-reduction Initiative and the R&D impairment cost, see page 28. 4 Adjusted EBIT = Operating income (EBIT) excluding items affecting comparability and the R&D impairment cost, see page 29. 5 Adjusted earnings per share = Net income excluding items affecting comparability, attributable to Parent Company shareholders, in relation to the weighted average number of shares (excluding treasury shares), see page 30 |
Strong growth in software and price increases contributed to the best Q4 gross margin in five years. Our latest linear accelerator, Elekta Evo, and the new additions to our software suite, Elekta ONE, continued to generate order and sales growth. A non-cash impairment amounting to SEK 1,064 M was booked in Q4 due to discontinued R&D projects.
In spite of a decline in orders in Q4, our book-to-bill ratio stands strong at 1.12 for Q4 and at 1.09 for the full year of 2024/25, mainly driven by our latest linear accelerator, Elekta Evo, and the new additions to our software suite, Elekta ONE. Net sales at constant exchange rates increased by 6 percent in Q4 and 1 percent for the full year, in line with our guidance.
I am pleased that we ended the year with a gross margin of 40.3 percent (36.6). This was the best Q4 gross margin in five years, an important step in our ambition to return to pre-pandemic levels. The EBIT margin ended at 16.3 percent (13.0) in Q4. Double-digit growth in our software business, price increases as well as product launches and a solid development for our specialty products contributed to the strong earnings momentum. Operating cash flow after continuous investments improved by SEK 241 M to SEK 1,056 M for the full year. The Board proposes a dividend of SEK 2.40 (2.40) per share to the AGM, underlining Elekta's strong financial position.
During the quarter we completed a review of Elekta's R&D assets on the balance sheet, which has resulted in a non-cash impairment amounting to SEK 1,064 M due to discontinued R&D projects. The impairment is mainly a consequence of a change of scope within software partly driven by moving from an internally developed cloud ware solution to an external supplier's platform.
In consultation with the U.S. Food and Drug Administration (FDA), we changed our regulatory submission strategy in mid-May for Elekta Evo to better align with the FDA´s approval process with greater focus on cybersecurity. We expect that the impact of this delay on the overall project launch will be limited. Meanwhile,

Elekta Evo and our software suite Elekta ONE are fully operational, currently in clinical use, and have received outstanding feedback from healthcare providers across Europe.
During the quarter, we delivered on several important commercial wins such as Elekta Evo, our software suite Elekta ONE, and a comprehensive deal comprising some of our most advanced solutions to the University of Texas Southwestern.
At the annual ESTRO congress in Vienna, there was great customer interest in our online adaptive treatment capabilities on Elekta Evo with Elekta ONE Planning, as well as Elekta Unity's superiority in preserving healthy tissue, not least manifested by the ERECT trial in Utrecht showing astounding results in maintaining erectile function for prostate cancer patients.
Despite present market conditions and current political and macro-economic visibility, net sales are expected to grow year-over-year. We expect Gross and EBIT margins to expand, driven by price increases, product launches and volumes, resulting in a stepwise improvement towards our midterm targets to move the gross margin to prepandemic levels and an EBIT margin of 14% and higher. For Q1 2025/26, we expect normal seasonal development with low sales volumes as well as negative FX-effects.
Jonas Bolander President and CEO
40.3% Q4 adj. gross margin
"The best Q4 gross margin in five years."
Based on constant exchange rates, Elekta's net sales increased by 6 percent in the fourth quarter. The development was mainly driven by strong performance in Europe and most markets in APAC while U.S. net sales continued to be weak. Reported net sales increased by 3 percent amounting to SEK 5,156 M (5,023).
Sales in EMEA increased by 16 percent in constant exchange rates compared to last year, driven by the continued strong momentum in Europe supported by new product launches. APAC sales grew by 5 percent in constant exchange rates with good performance across most markets. The Chinese market continued to remain soft, however improvements were seen during the quarter resulting in a limited sales decline of 1 percent compared to last year. In the Americas, the development was similar to the third quarter of fiscal year 2024/25 where growth in South America was fully offset by a weak development in
the U.S. mainly as a consequence of customers awaiting the Elekta Evo clearance.
Solutions and Service increased sales by 7 percent and 4 percent respectively in constant exchange rates supported by growth in software.
The book-to-bill ratio was 1.12 (1.28) in the fourth quarter and 1.09 (1.09) for the full year 2024/25. Gross order intake in the fourth quarter amounted to SEK 5,792 M (6,436), a decrease of 10 percent in SEK and 7 percent based on constant exchange rates.
For more information about the book-to-bill ratio, see page 30.
| Q4 Full year |
||||||||
|---|---|---|---|---|---|---|---|---|
| SEK M | 2024/25 | 2023/24 | 1 Δ |
Δ | 2024/25 | 2023/24 | 1 Δ |
Δ |
| Americas | 1,371 | 1,526 | -6% | -10% | 5,183 | 5,436 | -2% | -5% |
| EMEA | 2,014 | 1,769 | 16% | 14% | 6,580 | 6,550 | 1% | 0% |
| APAC | 1,771 | 1,728 | 5% | 2% | 6,253 | 6,134 | 4% | 2% |
| Group | 5,156 | 5,023 | 6% | 3% | 18,016 | 18,119 | 1% | -1% |
| Q4 | Full year | |||||||
|---|---|---|---|---|---|---|---|---|
| SEK M | 2024/25 | 2023/24 | 1 Δ |
Δ | 2024/25 | 2023/24 | 1 Δ |
Δ |
| Solutions | 3,186 | 3,060 | 7% | 4% | 10,232 | 10,633 | -2% | -4% |
| Service | 1,970 | 1,963 | 4% | 0% | 7,784 | 7,487 | 6% | 4% |
| Group | 5,156 | 5,023 | 6% | 3% | 18,016 | 18,119 | 1% | -1% |
1 Based on constant exchange rates.
FINANCIAL HIGHLIGHTS
In the fourth quarter, the adjusted gross income was SEK 2,075 M (1,837), representing an adjusted gross margin of 40.3 percent (36.6). The increase was supported by higher volumes, price improvements, and a favorable product mix with a larger share of high-margin devices as well as strong software growth. Changes in foreign exchange rates had a negative impact. Reported gross income amounted to SEK 2,053 M (1,829), representing a margin of 39.8 percent (36.4).
The fourth quarter results include a non-cash impairment amounting to SEK 1,064 M due to discontinued R&D projects, representing approximately 8% of total intangible and tangible assets on the balance sheet. Elekta is regularly performing asset impairment reviews in accordance with IFRS requirements. Following a change of direction of the product development roadmap during the quarter, some projects will not be continued or will not deliver according to the original business plan.
The impairment is reported as an item affecting comparability (IAC) and mainly includes items presented as R&D expenses. For more information, see note 5 and the presentation of IAC on page 27. Elekta expects that the impact from the impairment will amount to SEK 100 M in yearly lower amortization.
Adjusted EBIT came in at SEK 843 M (651), representing a margin of 16.3 percent (13.0). The higher adjusted EBIT margin derives mainly from the gross margin partially offset by higher amortization costs. Furthermore, changes in foreign exchange rates had a negative impact.
Reported EBIT, including the impairment, amounted to SEK -197 M (617), representing a margin of -3.8 percent (12.3). IAC in the fourth quarter amounted to SEK 1,040 M, of which SEK 1,064 M relates to the impairment partially offset by positive items mainly related to the impairment of SEK 24 M. IAC amounting to SEK 22 M (7) impacted the gross margin in Q4.
Operating expenses, excluding IAC and based on constant exchange rates, increased by 6 percent during the fourth quarter. The increase was mainly driven by higher amortization of intangible assets following recent product launches.
Net financial items increased slightly to SEK -109 M (-88), explained by higher interest expenses and a negative non-cash effect related to revaluation of the operations in Turkey with regards to its hyperinflation. Taxes amounted to SEK 74 M (115), representing a tax rate of 24 percent (22). Net income, impacted by the impairment, amounted to SEK -381 M (414) and earnings per share to SEK -1.01 (1.08) before and after dilution.
| Q4 | Full year | |||||
|---|---|---|---|---|---|---|
| SEK M | 2024/25 | 2023/24 | Δ | 2024/25 | 2023/24 | Δ |
| Net sales | 5,156 | 5,023 | 3% | 18,016 | 18,119 | -1% |
| Net sales in constant currency | 6% | 1% | ||||
| Adjusted gross income | 2,075 | 1,837 | 13% | 6,810 | 6,803 | 0% |
| Adjusted gross margin | 40.3% | 36.6% | 3.7 ppts | 37.8% | 37.5% | 0.3 ppts |
| Adjusted EBIT | 843 | 651 | 29% | 2,097 | 2,145 | -2% |
| Adjusted EBIT-margin | 16.3% | 13.0% | 3.4 ppts | 11.6% | 11.8% | -0.2 ppts |
| EBIT | -197 | 617 | -132% | 890 | 2,039 | -56% |
| EBIT-margin | -3.8% | 12.3% | -16.1 ppts | 4.9% | 11.3% | -6.3 ppts |
| Net income | -381 | 414 | -192% | 240 | 1,302 | -82% |
| Earnings per share | -1.01 | 1.08 | -193% | 0.62 | 3.41 | -82% |
As part of Elekta's ongoing efforts to improve cost efficiency, the company delivered on its previously announced Cost-reduction Initiative. On April 30, 2025, cost savings amounted to SEK 279 M in annual run rate savings with SEK 145 M impacting fiscal year 2024/25. The target was SEK 250 M in annual run rate savings at an estimated implementation cost of SEK 250 M. The costs amounted to SEK 189 M and are reported as items affecting comparability, see page 27.
The average number of employees on April 30, 2025, was 4,536 (4,607).
Total number of registered shares on April 30, 2025, was 383,568,409, of which 14,980,769 were A-shares and 368,587,640 B-shares. On April 30, 2025, 1,485,289 shares were treasury shares held by Elekta. Earnings per share was SEK -1.01 (1.08) before and after dilution.
Cash flow after continuous investments amounted to SEK 1,248 M (872), an increase of SEK 376 M compared to last year. The increase is mainly driven by higher EBITDA and lower investments. Full year 2024/25 net working capital as a percentage of net sales was -9 percent (-10).
Investments in intangible assets amounted to SEK 291 M (378) and were mainly related to R&D investments in new product solutions and software. Investments in tangible assets decreased to SEK 28 M (67). Cash conversion in the fourth quarter was 132 percent (142).
| Q4 | Full year | ||||
|---|---|---|---|---|---|
| SEK M | 2024/25 | 2023/24 | 2024/25 | 2023/24 | |
| EBITDA | 1,189 | 930 | 3,283 | 3,189 | |
| Change in w orking capital |
364 | 441 | -203 | -220 | |
| Financial net | -109 | -88 | -400 | -371 | |
| Paid tax | -15 | -27 | -311 | -431 | |
| Other | 139 | 63 | 258 | 295 | |
| Cash flow from operating activities |
1,568 | 1,317 | 2,626 | 2,461 | |
| Continuous investments | -320 | -445 | -1,570 | -1,645 | |
| Cash flow after continuous investments |
1,248 | 872 | 1,056 | 815 | |
| Operational cash conversion | 132% | 142% | 80% | 77% |
Cash and cash equivalents and short-term investments amounted to SEK 2,955 M (2,779). The increase compared to last year is driven by higher earnings and a positive net intake of cash between the bond issued on October 1, 2024, amounting to SEK 1,500 M and the repayment of a bond amounting to SEK 1,000 M on March 13, 2025. Interest-bearing liabilities, excluding lease liabilities, amounted to SEK 6,373 M (5,929).
Net debt increased to SEK 3,477 M (3,150) as a result of continuous investments in R&D innovation and acquisitions. Net debt in relation to EBITDA was 1.06 (0.99). The average maturity of interest-bearing liabilities was 3.3 years.
The Board of Directors proposes a dividend of SEK 2.40 (2.40) per share (paid in two installments) for 2024/25 amounting to SEK 917 M.
| Apr 30 | Apr 30 | |
|---|---|---|
| SEK M | 2025 | 2024 |
| Long-term interest-bearing liabilities | 6,195 | 4,807 |
| Short-term interest-bearing liabilities | 178 | 1,122 |
| Derivatives, net | 60 | - |
| Cash and cash equivalents and short-term investments |
-2,955 | -2,779 |
| Net debt | 3,477 | 3,150 |
| Long-term lease liabilities | 961 | 1,095 |
| Short-term lease liabilities | 233 | 224 |
| Net debt including lease liabilities | 4,671 | 4,469 |
| Net debt/EBITDA ratio 1 | 1.06 | 0.99 |
1 EBITDA 12 months rolling
Elekta's presence in many geographical markets exposes the Group to political and economic risks on a global scale and/or in individual countries. For more details, please see the Annual Report 2023/24, page 25. Recent updates to these risk factors and uncertainties, which Elekta considers to be of short-term relevance, include but are not limited to the following risks outlined below:
Geopolitical tensions, including tariffs, restrictions, protectionism and the expansion of sanctions may impact Elekta's local partnering, manufacturing and sales in certain markets, potentially exposing us to conflicting trade compliance sanctions.
This is information such that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication by the below mentioned contact persons at 07:30 CEST on May 28, 2025. This report includes forward-looking statements including, but not limited to, statements relating to operational and financial performance, market conditions, and other similar matters. These forwardlooking statements are based on current expectations about future events. Although the expectations described in these statements are assumed to be reasonable, there is no guarantee that such forward-looking statements will materialize or are accurate. Since these statements involve assumptions and estimates that are subject to risks and uncertainties, results could differ materially from those set out in the statement. Some of these risks and uncertainties are described further in the section "Risk and uncertainties". Elekta undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or stock exchange regulations.
During the year, operating income and expenses have increased due to higher support in relation to expenses. Operating income increased due to higher finance net
that was positively affected by increased dividends from subsidiaries partly offset by an impairment of shares in subsidiaries of SEK 404 M.
All external loans are considered long-term in the fourth quarter of fiscal year 2024/25 in comparison to last year when SEK 1,000 M was short-term.
Elekta announced that Gustaf Salford, President and CEO, and the Board of Directors, have decided that Gustaf will leave Elekta as of March 6. Jonas Bolander, Executive Vice President, General Counsel & Head of Group Functions, will assume the CEO position until a new CEO is in office.
Elekta and Azra AI announce partnership to enhance cancer registry operations with AI-powered automation Elekta announced that it has partnered with Azra AI, the industry's only end-to-end oncology workflow automation platform, to enhance cancer registry operations through automation and AI-powered data management.
Clinical trial shows more precise radiotherapy using Elekta Unity MR-Linac preserves sexual function in men with prostate cancer
ERECT trial used MR-guidance to spare nerves and blood vessels essential for achieving and maintaining an erection.
Elekta will host a web conference at 10:00-11:00 CEST on May 28 with President and CEO Jonas Bolander, and CFO Tobias Hägglöv. To take part of the presentation please dial the numbers or watch via the web link below.
Sweden: +46 (0) 8 5051 0031 UK: +44 (0) 207 107 06 13 USA: +1 (1) 631 570 56 13
Tobias Hägglöv CFO +46 76 107 4799 [email protected]
Peter Nyquist VP, Head of Investor Relations +46 70 575 2906 [email protected]
Annual Report 2024/25 Jul 4, 2025 Interim report, Q1, May-Jul 2025/26 Aug 28, 2025 Annual General Meeting 2025 Sep 4, 2025 Interim report, Q2, May-Oct 2025/26 Nov 26, 2025 Interim report, Q3, May-Jan 2025/26 Mar 5, 2026 Interim report, Q4, May-Apr 2025/26 May 28, 2026
Stockholm May 28, 2025
Jonas Bolander President and CEO
This report has not been reviewed by the Company's auditors.
| Q4 | Full year | |||
|---|---|---|---|---|
| SEK M Note |
2024/25 | 2023/24 | 2024/25 | 2023/24 |
| Net sales 3 |
5,156 | 5,023 | 18,016 | 18,119 |
| Cost of products sold | -3,102 | -3,194 | -11,270 | -11,342 |
| Gross income | 2,053 | 1,829 | 6,746 | 6,777 |
| Selling expenses | -411 | -411 | -1,650 | -1,641 |
| Administrative expenses | -363 | -366 | -1,412 | -1,370 |
| R&D expenses | -1,376 | -354 | -2,676 | -1,404 |
| Other operating income and expenses | -56 | -29 | -108 | -102 |
| Exchange rate differences | -45 | -51 | - 9 |
-221 |
| Operating income (EBIT) | -197 | 617 | 890 | 2,039 |
| Financial items, net | -109 | -88 | -400 | -371 |
| Income after financial items | -307 | 529 | 490 | 1,668 |
| Income tax | -74 | -115 | -250 | -365 |
| Net income for the period 2 |
-381 | 414 | 240 | 1,302 |
| Net income for the period attributable to: | ||||
| Parent Company shareholders | -386 | 415 | 237 | 1302 |
| Non-controlling interests | 5 | 0 | 4 | 0 |
| Earnings per share | ||||
| Before dilution, SEK | -1.01 | 1.08 | 0.62 | 3.41 |
| After dilution, SEK | -1.01 | 1.08 | 0.62 | 3.41 |
| SEK M 2024/25 2023/24 2024/25 2023/24 Net income for the period -381 414 240 1,302 Other comprehensive income: Items that w ill not be reclassified to the income statement: Remeasurements of defined benefit pension plans 1 - 8 1 - 8 Tax - 3 1 - 3 1 Total items that will not be reclassified to the income statement - 2 - 7 - 2 - 7 Items that subsequently may be reclassified to the income statement: Revaluation of cash flow hedges 169 -49 94 81 Translation differences from foreign operations -1,281 609 -1,385 583 Tax -35 10 -19 -17 Total items that subsequently may be reclassified to the income statement -1,147 570 -1,311 648 Other comprehensive income for the period -1,149 564 -1,312 641 Total comprehensive income for the period -1,530 978 -1,072 1,943 Comprehensive income attributable to: Parent Company shareholders -1,529 978 -1,072 1,942 Non-controlling interests - 1 0 0 1 |
Q4 | Full year | ||
|---|---|---|---|---|
| Apr 30 | ||
|---|---|---|
| SEK M Note |
2025 | 2024 |
| Non-current assets | ||
| Intangible assets | 11,917 | 13,336 |
| Right-of-use assets 5 |
1,006 | 1,164 |
| Tangible assets | 901 | 1,062 |
| Financial assets | 895 | 1,092 |
| Deferred tax assets | 841 | 801 |
| Total non-current assets | 15,560 | 17,455 |
| Current assets | ||
| Inventories | 2,756 | 3,259 |
| Accounts receivable | 3,625 | 3,877 |
| Accrued income | 2,261 | 2,050 |
| Other current receivables | 1,820 | 1,994 |
| Cash and cash equivalents | 2,955 | 2,779 |
| Total current assets | 13,417 | 13,958 |
| Total assets | 28,977 | 31,413 |
| Equity attributable to Parent Company shareholders | 8,803 | 10,774 |
| Non-controlling interests | 45 | 5 |
| Total equity | 8,848 | 10,779 |
| Non-current liabilities | ||
| Interest-bearing liabilities 4 |
6,195 | 4,807 |
| Lease liabilities | 961 | 1,095 |
| Other non-current liabilities | 626 | 736 |
| Total non-current liabilities | 7,781 | 6,639 |
| Current liabilities | ||
| Interest-bearing liabilities 4 |
178 | 1,122 |
| Lease liabilities | 233 | 224 |
| Accounts payable | 1,837 | 1,550 |
| Advances from customers | 4,067 | 4,893 |
| Prepaid income | 2,831 | 2,945 |
| Accrued expenses | 2,245 | 2,212 |
| Other current liabilities | 957 | 1,051 |
| Total current liabilities | 12,348 | 13,996 |
| Total equity and liabilities | 28,977 | 31,413 |
| Apr 30 | ||
|---|---|---|
| SEK M | 2024/25 | 2023/24 |
| Attributable to Parent Company shareholders | ||
| Opening balance | 10,774 | 9,729 |
| Comprehensive income for the period | -1,072 | 1,942 |
| Incentive programs | 18 | 19 |
| Dividend | -917 | -917 |
| Total | 8,803 | 10,774 |
| Attributable to non-controlling interests | ||
| Opening balance | 5 | 4 |
| Comprehensive income for the period | 0 | 1 |
| Acquisition of non-controlling interest | 40 | - |
| Total | 45 | 5 |
| Closing balance | 8,848 | 10,779 |
| Q4 | Full year | ||||
|---|---|---|---|---|---|
| SEK M | 2024/25 | 2023/24 | 2024/25 | 2023/24 | |
| Income after financial items | -307 | 529 | 490 | 1,668 | |
| Amortization and depreciation | 322 | 299 | 1,299 | 1,136 | |
| Impairment | 1,064 | 13 | 1,094 | 13 | |
| Interest net | 120 | 92 | 382 | 306 | |
| Other non-cash items | 164 | 80 | 263 | 247 | |
| Interest received and paid | -145 | -109 | -388 | -257 | |
| Income taxes paid | -15 | -27 | -311 | -431 | |
| Operating cash flow | 1,204 | 877 | 2,829 | 2,681 | |
| Change in inventories | 302 | 357 | 325 | -93 | |
| Change in operating receivables | -197 | 602 | -657 | 313 | |
| Change in operating liabilities | 259 | -518 | 128 | -441 | |
| Change in working capital | 364 | 441 | -203 | -220 | |
| Cash flow from operating activities | 1,568 | 1,317 | 2,626 | 2,461 | |
| Investments in intangible assets | -291 | -378 | -1,370 | -1,392 | |
| Investments in tangible assets | -28 | -67 | -200 | -254 | |
| Continuous investments | -320 | -445 | -1,570 | -1,645 | |
| Cash flow after continuous investments | 1,248 | 872 | 1,056 | 815 | |
| Business combinations and investments in other shares | 0 | - | -102 | -278 | |
| Cash flow after investments | 1,248 | 872 | 954 | 538 | |
| Dividends | -458 | -458 | -917 | -917 | |
| Cash flow from other financing activities |
-1,187 | -65 | 310 | -182 | |
| Cash flow for the period | -397 | 348 | 347 | -562 | |
| Change in cash and cash equivalents during the period | |||||
| Cash and cash equivalents at the beginning of the period | 3,583 | 2,352 | 2,779 | 3,278 | |
| Cash flow for the period |
-397 | 348 | 347 | -562 | |
| Exchange rate differences | -230 | 79 | -170 | 62 | |
| Cash and cash equivalents at the end of the period | 2,955 | 2,779 | 2,955 | 2,779 |
| Full year | ||
|---|---|---|
| SEK M | 2024/25 | 2023/24 |
| Operating income and expenses | 49 | -31 |
| Financial net | 561 | 350 |
| Income after financial items | 610 | 319 |
| Tax | - 3 |
- 4 |
| Net income for the period | 607 | 316 |
| Statement of comprehensive income | ||
| Net income for the period | 607 | 316 |
| Total comprehensive income | 607 | 316 |
| Apr 30 | Apr 30 | |
|---|---|---|
| SEK M | 2025 | 2024 |
| Non-current assets | ||
| Intangible assets | 14 | 18 |
| Shares in subsidiaries | 4,530 | 4,829 |
| Receivables from subsidaries | 1,676 | 1,705 |
| Other financial assets | 36 | 29 |
| Deferred tax assets | 33 | 26 |
| Total non-current assets | 6,289 | 6,608 |
| Current assets | ||
| Receivables from subsidaries | 3,811 | 3,496 |
| Other current receivables | 76 | 86 |
| Cash and cash equivalents | 1,360 | 1,472 |
| Total current assets | 5,247 | 5,054 |
| Total assets | 11,536 | 11,662 |
| Shareholders' equity | 1,685 | 1,988 |
| Non-current liabilities | ||
| Interest-bearing liabilities | 6,248 | 4,807 |
| Provisions | 22 | 16 |
| Total non-current liabilities | 6,270 | 4,823 |
| Current liabilities | ||
| Interest-bearing liabilities | - | 1,000 |
| Liabilities to Group companies | 3,462 | 3,750 |
| Other current liabilities | 119 | 101 |
| Total current liabilities | 3,581 | 4,851 |
| Total shareholders' equity and liabilities | 11,536 | 11,662 |
| Full-year | May - Apr | ||||
|---|---|---|---|---|---|
| 2019/20 | 2020/21 | 2021/22 | 2022/23 | 2023/24 | 2024/25 |
| 17,735 | 17,411 | 18,364 | 20,143 | 19,697 | 19,718 |
| 14,601 | 13,763 | 14,548 | 16,869 | 18,119 | 18,016 |
| 42.0 | 40.8 | 37.4 | 37.6 | 37.4 | 37.4 |
| 42.0 | 40.8 | 37.4 | 38.1 | 37.5 | 37.8 |
| 1,657 | 1,906 | 1,643 | 1,431 | 2,039 | 890 |
| 11.3 | 13.9 | 11.3 | 8.5 | 11.3 | 4.9 |
| 1,657 | 1,906 | 1,643 | 1,743 | 2,145 | 2,097 |
| 11.3 | 13.9 | 11.3 | 10.3 | 11.8 | 11.6 |
| 8,113 | 8,197 | 8,913 | 9,729 | 10,774 | 8,803 |
| 14 | 16 | 14 | 10 | 13 | 2 |
| 1,632 | 774 | 1,532 | 2,442 | 3,150 | 3,477 |
| 35 | 82 | 69 | 76 | 77 | 80 |
| 4,117 | 4,194 | 4,631 | 4,587 | 4,607 | 4,536 |
1 Attributable to Parent Company shareholders.
| Full-year | May - Apr | |||||
|---|---|---|---|---|---|---|
| 2019/20 | 2020/21 | 2021/22 | 2022/23 | 2023/24 | 2024/25 | |
| Earnings per share | ||||||
| before dilution, SEK | 2.84 | 3.28 | 3.02 | 2.47 | 3.41 | 0.62 |
| after dilution, SEK | 2.84 | 3.28 | 3.02 | 2.47 | 3.41 | 0.62 |
| Adjusted earnings per share | ||||||
| before dilution, SEK | 2.84 | 3.28 | 3.02 | 3.11 | 3.62 | 3.08 |
| after dilution, SEK | 2.84 | 3.28 | 3.02 | 3.10 | 3.62 | 3.08 |
| Cash flow per share | ||||||
| before dilution, SEK | -0.74 | 5.07 | 0.55 | 0.91 | 1.41 | 2.50 |
| after dilution, SEK | -0.74 | 5.07 | 0.55 | 0.91 | 1.41 | 2.50 |
| Shareholders' equity per share | ||||||
| before dilution, SEK | 21.23 | 21.45 | 23.33 | 25.46 | 28.20 | 23.04 |
| after dilution, SEK | 21.23 | 21.45 | 23.33 | 25.44 | 28.20 | 23.04 |
| Average number of shares | ||||||
| before dilution, thousands | 382,062 | 382,083 | 382,083 | 382,083 | 382,083 | 382,083 |
| after dilution, thousands | 382,062 | 382,083 | 382,083 | 382,367 | 382,086 | 382,139 |
| Number of shares at closing 1 | ||||||
| before dilution, thousands | 382,083 | 382,083 | 382,083 | 382,083 | 382,083 | 382,083 |
| after dilution, thousands | 382,083 | 382,083 | 382,083 | 382,575 | 382,086 | 382,135 |
1 Number of registered shares at closing excluding treasury shares (1,485,289 per April 30, 2025).
| 2022/23 | 2023/24 | 2024/25 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| SEK M | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 |
| Gross order intake | 6,359 | 3,839 | 4,989 | 4,433 | 6,436 | 4,192 | 4,317 | 5,418 | 5,792 |
| Net sales | 5,125 | 3,828 | 4,732 | 4,537 | 5,023 | 3,825 | 4,341 | 4,695 | 5,156 |
| Operating income (EBIT) | 784 | 412 | 525 | 485 | 617 | 174 | 388 | 525 | -197 |
| Cash flow from operating activities |
1,991 | -551 | 623 | 1,072 | 1,317 | -493 | 456 | 1,095 | 1,568 |
| Q4 | Full year | ||||
|---|---|---|---|---|---|
| SEK M | 2024/25 | 2023/24 | 2024/25 | 2023/24 | |
| R&D expenditure, gross | 479 | 578 | 2,217 | 2,224 | |
| Capitalization | -274 | -362 | -1,207 | -1,331 | |
| Amortization | 169 | 137 | 663 | 511 | |
| Impairment | 1,002 | - | 1,002 | - | |
| R&D expenditure, net | 1,376 | 354 | 2,676 | 1,404 |
This interim report is prepared, with regards to the Group, according to IAS 34 and the Swedish Annual Accounts Act and, with regards to the Parent Company, according to the Swedish Annual Accounts Act and RFR 2. The accounting principles applied are consistent with those presented in Note 1 of the Annual Report 2023/24.
New or revised standards and interpretations, not yet applied, are not considered to have a material impact on the Elekta Group´s financial statements.
All figures are stated in SEK M and, accordingly, rounding differences can occur. Comparisons refer to the corresponding period for the prior year, unless otherwise stated.
Definitions can be found on pages 103-105 in the Annual Report 2023/24.
Related party transactions are described in note 37 in the Annual Report for 2023/24. The consultancy agreements with two board members that existed in FY 2023/24 have been terminated.
For Group companies with a functional currency other than Swedish kronor, order intake and income statements are translated at average exchange rates for the reporting period, while balance sheets are translated at closing exchange rates.
| Country | Currency | Average rate | Closing rate | ||||
|---|---|---|---|---|---|---|---|
| Q4 | Apr 30 | ||||||
| 2025 | 2024 | 1 Δ |
2025 | 2024 | 1 Δ |
||
| China | 1 CNY | 1.462 | 1.478 | -1% | 1.328 | 1.513 | -12% |
| Euroland | 1 EUR | 11.374 | 11.514 | -1% | 10.977 | 11.729 | -6% |
| Great Britain | 1 GBP | 13.522 | 13.368 | 1% | 12.924 | 13.744 | -6% |
| Japan | 1 JPY | 0.070 | 0.073 | -4% | 0.068 | 0.070 | -3% |
| United States | 1 USD | 10.560 | 10.635 | -1% | 9.651 | 10.955 | -12% |
1 April 30, 2025, vs April 30, 2024.
Elekta applies geographical segmentation. Net sales and contribution margin for the respective regions are reported to Elekta's CFO and CEO (chief operating decision makers). The regions' expenses are directly attributable to the respective regions' reported figures including cost of products sold. Global costs for R&D, marketing, management of product supply centers and Parent Company are not allocated per region. Currency exposure is concentrated to product supply centers. The majority of exchange differences in operations are reported in global costs.
Elekta's operations are characterized by significant quarterly variations in volumes and product mix, which have a direct impact on net sales and profits. This is accentuated when the operation is split into segments, as is the impact of currency fluctuations between the years. In general, revenue from Solutions is recognized at a point in time and revenue from Services are recognized over time.
| Other / | Group | |||||
|---|---|---|---|---|---|---|
| SEK M | Americas | EMEA | APAC | Group-wide | total | % of net sales |
| Net sales | 1,371 | 2,014 | 1,771 | - | 5,156 | |
| Operating expenses | -914 | -1,210 | -1,095 | - | -3,219 | 62% |
| Contribution margin | 457 | 804 | 676 | - | 1,937 | 38% |
| Contribution margin, % | 33% | 40% | 38% | |||
| Global costs | - | - | - | -1,094 | -1,094 | 21% |
| Adjusted EBIT | 457 | 804 | 676 | -1,094 | 843 | 16% |
| Items affecting comparability1 | 0 | - 6 |
0 | -1,034 | -1,040 | |
| Operating income (EBIT) | 457 | 798 | 676 | -2,128 | -197 | -4% |
| Net financial items | - | - | - | -109 | -109 | |
| Income after financial items | 457 | 798 | 676 | -2,237 | -307 | |
| Income tax | - | - | - | -74 | -74 | |
| Net income for the period | 457 | 798 | 676 | -2,312 | -381 |
| Other / | Group | |||||
|---|---|---|---|---|---|---|
| SEK M | Americas | EMEA | APAC | Group-wide | total | % of net sales |
| Net sales | 1,526 | 1,769 | 1,728 | - | 5,023 | |
| Operating expenses | -923 | -1,259 | -1,184 | - | -3,366 | 67% |
| Contribution margin | 604 | 510 | 543 | - | 1,657 | 33% |
| Contribution margin, % | 40% | 29% | 31% | |||
| Global costs | - | - | - | -1,006 | -1,006 | 20% |
| Adjusted EBIT | 604 | 510 | 543 | -1,006 | 651 | 13% |
| Items affecting comparability1 | - 8 |
- 1 |
0 | -26 | -34 | |
| Operating income (EBIT) | 596 | 510 | 543 | -1,032 | 617 | 12% |
| Net financial items | - | - | - | -88 | -88 | |
| Income after financial items | 596 | 510 | 543 | -1,120 | 529 | |
| Income tax | - | - | - | -115 | -115 | |
| Net income for the period | 596 | 510 | 543 | -1,235 | 414 |
1 Items affecting comparability include mainly personnel costs and impairments of assets attributable to the Cost-reduction Initiative and the R&D impairment cost.
| Other / | Group | |||||
|---|---|---|---|---|---|---|
| SEK M | Americas | EMEA | APAC | Group-wide | total | % of net sales |
| Net sales | 5,183 | 6,580 | 6,253 | - | 18,016 | |
| Operating expenses | -3,216 | -4,247 | -4,020 | - | -11,482 | 64% |
| Contribution margin | 1,967 | 2,333 | 2,233 | - | 6,534 | 36% |
| Contribution margin, % | 38% | 35% | 36% | |||
| Global costs | - | - | - | -4,437 | -4,437 | 25% |
| Adjusted EBIT | 1,967 | 2,333 | 2,233 | -4,437 | 2,097 | 12% |
| Items affecting comparability1 | -21 | -12 | - 9 |
-1,164 | -1,207 | |
| Operating income (EBIT) | 1,946 | 2,321 | 2,224 | -5,601 | 890 | 5% |
| Net financial items | - | - | - | -400 | -400 | |
| Income after financial items | 1,946 | 2,321 | 2,224 | -6,001 | 490 | |
| Income tax | - | - | - | -250 | -250 | |
| Net income for the period | 1,946 | 2,321 | 2,224 | -6,251 | 240 |
| Other / | Group | |||||
|---|---|---|---|---|---|---|
| SEK M | Americas | EMEA | APAC | Group-wide | total | % of net sales |
| Net sales | 5,436 | 6,550 | 6,134 | - | 18,119 | |
| Operating expenses | -3,358 | -4,527 | -4,294 | - | -12,179 | 67% |
| Contribution margin | 2,078 | 2,023 | 1,840 | - | 5,940 | 33% |
| Contribution margin, % | 38% | 31% | 30% | |||
| Global costs | - | - | - | -3,795 | -3,795 | 21% |
| Adjusted EBIT | 2,078 | 2,023 | 1,840 | -3,795 | 2,145 | 12% |
| Items affecting comparability1 | - 8 |
- 9 |
- 6 |
-83 | -106 | |
| Operating income (EBIT) | 2,070 | 2,014 | 1,834 | -3,879 | 2,039 | 11% |
| Net financial items | - | - | - | -371 | -371 | |
| Income after financial items | 2,070 | 2,014 | 1,834 | -4,250 | 1,668 | |
| Income tax | - | - | - | -365 | -365 | |
| Net income for the period | 2,070 | 2,014 | 1,834 | -4,615 | 1,302 |
1 Items affecting comparability include mainly personnel costs and impairments of assets attributable to the Cost-reduction Initiative and the R&D impairment cost.
In general, net sales from Solutions is taken at a point in time, net sales from Service is taken over time.
| SEK M | Americas | EMEA | APAC | Group total |
|---|---|---|---|---|
| Solutions | 642 | 1,265 | 1,279 | 3,186 |
| Service | 729 | 749 | 491 | 1,970 |
| Total | 1,371 | 2,014 | 1,771 | 5,156 |
| SEK M | Americas | EMEA | APAC | Group total |
|---|---|---|---|---|
| Solutions | 711 | 1,072 | 1,277 | 3,060 |
| Service | 815 | 697 | 450 | 1,963 |
| Total | 1,526 | 1,769 | 1,728 | 5,023 |
| SEK M | Americas | EMEA | APAC | Group total |
|---|---|---|---|---|
| Solutions | 2,181 | 3,694 | 4,358 | 10,232 |
| Service | 3,002 | 2,886 | 1,896 | 7,784 |
| Total | 5,183 | 6,580 | 6,253 | 18,016 |
| SEK M | Americas | EMEA | APAC | Group total |
|---|---|---|---|---|
| Solutions | 2,346 | 3,883 | 4,404 | 10,633 |
| Service | 3,090 | 2,666 | 1,730 | 7,487 |
| Total | 5,436 | 6,550 | 6,134 | 18,119 |
The table below shows the fair value of the Group's financial instruments, for which fair value is different than carrying value. The fair value of all other financial instruments is assumed to correspond to the carrying value.
| Apr 30, 2025 | Apr 30, 2024 | |||
|---|---|---|---|---|
| SEK M | Carrying amount |
Fair value |
Carrying amount |
Fair value |
| Long-term interest-bearing liabilities | 6,195 | 6,505 | 4,807 | 5,531 |
| Short-term interest-bearing liabilities | 178 | 178 | 1,122 | 1,174 |
The Group's financial assets and financial liabilities, which have been measured at fair value, have been categorized in the fair value hierarchy. The different levels are defined as follows:
| SEK M | Level | Apr 30, 2025 | Apr 30, 2024 |
|---|---|---|---|
| FINANCIAL ASSETS | |||
| Financial assets measured at fair value through income statement: | |||
| Derivative financial instruments – non-hedge accounting | 2 | 33 | 42 |
| Short-term investments classified as cash equivalents | 1 | - | - |
| Derivatives used for hedging purposes: | |||
| Derivative financial instruments – hedge accounting | 2 | 174 | 149 |
| Total financial assets measured at fair value | 207 | 190 | |
| FINANCIAL LIABILITIES | |||
| Financial liabilities at fair value through income statement: | |||
| Derivative financial instruments – non-hedge accounting | 2 | 79 | 11 |
| Contingent considerations | 3 | 75 | 76 |
| Derivatives used for hedging purposes: | |||
| Derivative financial instruments – hedge accounting | 2 | 51 | 120 |
| Total financial liabilities measured at fair value | 205 | 207 |
| SEK M | Apr 30, 2025 | Apr 30, 2024 |
|---|---|---|
| Opening balance | 76 | 21 |
| Business combinations | 48 | 68 |
| Payments | -43 | -12 |
| Reported in net income for the period | 1 | - |
| Translation differences | -6 | -2 |
| Closing balance | 75 | 76 |
The fair value of accounts receivables, other current and non-current receivables, cash and cash equivalents, accounts payable and other current and non-current liabilities is estimated to be equal to their carrying amount.
| SEK M | Intangible assets | Leases | Tangible assets | Total |
|---|---|---|---|---|
| Opening Balance, May 1 2024 | 13,336 | 1,164 | 1,062 | 15,562 |
| Additions | 1,534 | 225 | 200 | 1,958 |
| Depreciation | -841 | -241 | -218 | -1,299 |
| Impairment | -1,013 | -38 | -43 | -1,094 |
| Translation differences | -1,116 | -72 | -83 | -1,271 |
| Other items | 16 | -31 | -18 | -33 |
| Closing Balance, April 30 2025 | 11,917 | 1,006 | 901 | 13,823 |
Alternative Performance Measures (APMs) are measures and key figures that Elekta's management and other stakeholders use when managing and analyzing Elekta's business performance. These measures are not substitutes, but rather supplements to financial reporting measures prepared in accordance with IFRS. Key figures and other APMs used by Elekta are defined on ir.elekta.com/investors/financials. Definitions and additional information on APMs can also be found on pages 103-105 in the Annual Report 2023/24.
Sales growth based on constant exchange are, to a large extent, reported in subsidiaries with other functional currencies than SEK, which is the group reporting currency. In order to present sales growth on a more comparable basis and to show the impact of currency fluctuations, sales growth based on constant exchange rates are presented. The schedule below present growth based on constant exchange rates reconciled to the total growth reported in accordance with IFRS.
| Americas | EMEA | APAC | Group total | |||||
|---|---|---|---|---|---|---|---|---|
| % | SEK M | % | SEK M | % | SEK M | % | SEK M | |
| Q4 2024/25 vs. Q4 2023/24 | ||||||||
| Change based on constant exchange rates | - 6 |
-94 | 16 | 288 | 5 | 91 | 6 | 286 |
| Currency effects | - 4 |
-62 | - 2 |
-43 | - 3 |
-48 | - 3 |
-153 |
| Reported change | -10 | -156 | 14 | 246 | 2 | 43 | 3 | 133 |
| Q4 2023/24 vs. Q4 2022/23 | ||||||||
| Change based on constant exchange rates | - 2 |
-26 | - 6 |
-119 | 2 | 29 | - 2 |
-116 |
| Currency effects | 1 | 20 | 1 | 28 | - 2 |
-33 | 0 | 14 |
| Reported change | 0 | - 6 |
- 5 |
-91 | 0 | - 5 |
- 2 |
-102 |
| May - Apr 2024/25 vs. May - Apr 2023/24 | ||||||||
| Change based on constant exchange rates | - 2 |
-132 | 1 | 98 | 4 | 224 | 1 | 190 |
| Currency effects | - 2 |
-121 | - 1 |
-67 | - 2 |
-105 | - 2 |
-293 |
| Reported change | - 5 |
-253 | 0 | 30 | 2 | 119 | - 1 |
-103 |
| May - Apr 2023/24 vs. May - Apr 2022/23 | ||||||||
| Change based on constant exchange rates | 1 | 70 | 6 | 357 | 8 | 461 | 5 | 887 |
| Currency effects | 2 | 128 | 5 | 286 | - 1 |
-50 | 2 | 363 |
| Reported change | 4 | 197 | 11 | 643 | 7 | 410 | 7 | 1,250 |
Management reviews the development of expenses excluding items affecting comparability in constant currencies. The schedule below illustrates the reported change in expenses for items affecting comparability and the remaining change split between change based on constant exchange rates and change due to currency movements.
| Administrative | ||||||||
|---|---|---|---|---|---|---|---|---|
| Selling expenses expenses R&D expenses |
Change expenses | |||||||
| % | SEK M | % | SEK M | % | SEK M | % | SEK M | |
| Q4 2024/25 vs. Q4 2023/24 | ||||||||
| Change in items affecting comparability | 5 | 22 | 0 | -1 | 274 | 959 | 89 | 980 |
| Change based on constant exchange rates | -2 | -9 | 0 | 1 | 21 | 73 | 6 | 65 |
| Currency effects | -3 | -14 | -1 | -4 | -3 | -10 | -2 | -28 |
| Reported change | 0 | 0 | -1 | -4 | 292 | 1,022 | 92 | 1,018 |
| Q4 2023/24 vs. Q4 2022/23 | ||||||||
| Change in items affecting comparability | 2 | 8 | 5 | 16 | 1 | 4 | 3 | 28 |
| Change based on constant exchange rates | 5 | 18 | 15 | 45 | 20 | 58 | 12 | 121 |
| Currency effects | -1 | -3 | -1 | -2 | 0 | 1 | 0 | -4 |
| Reported change | 6 | 22 | 19 | 59 | 22 | 63 | 15 | 144 |
| May - Apr 2024/25 vs. May - Apr 2023/24 | ||||||||
| Change in items affecting comparability | 1 | 21 | 1 | 18 | 73 | 1,013 | 24 | 1,052 |
| Change based on constant exchange rates | 1 | 19 | 1 | 8 | 19 | 268 | 7 | 296 |
| Currency effects | -2 | -31 | 1 | 17 | -1 | -9 | -1 | -24 |
| Reported change | 1 | 9 | 3 | 43 | 91 | 1,272 | 31 | 1,323 |
| May - Apr 2023/24 vs. May - Apr 2022/23 | ||||||||
| Change in items affecting comparability | 2 | 29 | 3 | 42 | 1 | 10 | 2 | 82 |
| Change based on constant exchange rates | 3 | 45 | 0 | 2 | 1 | 16 | 2 | 63 |
| Currency effects | 1 | 17 | 5 | 60 | 2 | 26 | 2 | 103 |
| Reported change | 6 | 91 | 8 | 104 | 4 | 52 | 6 | 247 |
EBITDA is used for the calculation of operational cash conversion and the net debt/EBITDA ratio.
| SEK M | Q4 2023/24 | Q1 2024/25 | Q2 2024/25 | Q3 2024/25 | Q4 2024/25 |
|---|---|---|---|---|---|
| Operating income (EBIT) | 617 | 174 | 388 | 525 | -197 |
| Amortization intangible assets: | |||||
| Capitalized development costs | 139 | 159 | 165 | 179 | 172 |
| Assets relating to other intangibles | 34 | 39 | 40 | 45 | 41 |
| Depreciation tangible assets | 127 | 119 | 116 | 114 | 109 |
| Impairment | 13 | 31 | - 3 |
3 | 1,064 |
| EBITDA | 930 | 522 | 706 | 866 | 1,189 |
Return on shareholders' equity measures the return generated on shareholders' capital invested in the company.
| SEK M | Q4 2023/24 | Q1 2024/25 | Q2 2024/25 | Q3 2024/25 | Q4 2024/25 |
|---|---|---|---|---|---|
| Net income (12 months rolling) | 1,302 | 1,134 | 1,002 | 1,037 | 237 |
| Average shareholders' equity excluding non-controlling interests (last five quarters) |
10,266 | 10,460 | 10,502 | 10,585 | 10,297 |
| Return on shareholders' equity | 13% | 11% | 10% | 10% | 2% |
Cash flow is a focus area for management. The operational cash conversion shows the relation between cash flow from operating activities and EBITDA.
| SEK M | Q4 2023/24 | Q1 2024/25 | Q2 2024/25 | Q3 2024/25 | Q4 2024/25 |
|---|---|---|---|---|---|
| Cash flow from operating activities |
1,317 | -493 | 456 | 1,095 | 1,568 |
| EBITDA | 930 | 522 | 706 | 866 | 1,189 |
| Operational cash conversion | 142% | -95% | 65% | 126% | 132% |
In order to optimize cash generation, management focuses on working capital and reducing lead times between orders booked and cash received.
| Apr 30 | Apr 30 | |
|---|---|---|
| SEK M | 2025 | 2024 |
| Working capital assets | ||
| Inventories | 2,756 | 3,259 |
| Accounts receivable | 3,625 | 3,877 |
| Accrued income | 2,261 | 2,050 |
| Other operating receivables | 1,308 | 1,411 |
| Sum working capital assets | 9,950 | 10,596 |
| Working capital liabilities | ||
| Accounts payable | 1,837 | 1,550 |
| Advances from customers | 4,067 | 4,893 |
| Prepaid income | 2,831 | 2,945 |
| Accrued expenses | 2,245 | 2,212 |
| Short-term provisions | 148 | 148 |
| Other current liabilities | 516 | 595 |
| Sum working capital liabilities | 11,644 | 12,342 |
| Net working capital | -1,694 | -1,746 |
| % of rolling 12 months net sales | -9% | -10% |
Net debt is important for understanding the financial stability of the company. Net debt and net debt/EBITDA ratio are used by management to track the debt evolvement, the refinancing need and the leverage for the Group.
| SEK M | Apr 30, 2024 | Jul 31, 2024 | Oct 31, 2024 | Jan 31, 2025 | Apr 30, 2025 |
|---|---|---|---|---|---|
| Long-term interest-bearing liabilities | 4,807 | 4,811 | 6,307 | 6,291 | 6,195 |
| Short-term interest-bearing liabilities | 1,122 | 1,679 | 1,747 | 1,330 | 178 |
| Derivatives, net | - | - | 0 | 10 | 60 |
| Cash and cash equivalents and short-term investments | -2,779 | -2,364 | -3,352 | -3,583 | -2,955 |
| Net debt | 3,150 | 4,126 | 4,702 | 4,047 | 3,477 |
| EBITDA (12 months rolling) | 3,189 | 3,018 | 2,925 | 3,025 | 3,283 |
| Net debt/EBITDA ratio | 0.99 | 1.37 | 1.61 | 1.34 | 1.06 |
Items affecting comparability include cost attributable to the Cost-reduction Initiative. The costs are adjusted in order to track the underlying profitability of the Group's products and services.
| SEK M | Americas | EMEA | APAC | Other / Group-wide |
Group total |
|---|---|---|---|---|---|
| Items affecting comparability: | |||||
| Personnel related cost | 0 | 6 | 0 | 3 | 9 |
| Depreciation and impairment | - | - | 0 | 1,064 | 1,064 |
| Other cost | - | 0 | 0 | -33 | -33 |
| Total | 0 | 6 | 0 | 1,034 | 1,040 |
| SEK M | Americas | EMEA | APAC | Other / Group-wide |
Group total |
|---|---|---|---|---|---|
| Items affecting comparability: | |||||
| Personnel related cost | 8 | 0 | -0 | 15 | 23 |
| Depreciation and impairment | - | 0 | - | 7 | 8 |
| Other cost | - | 0 | - | 3 | 4 |
| Total | 8 | 1 | 0 | 26 | 34 |
| SEK M | Americas | EMEA | APAC | Other / Group-wide |
Group total |
|---|---|---|---|---|---|
| Items affecting comparability: | |||||
| Personnel related cost | 21 | 12 | 9 | 88 | 130 |
| Depreciation and impairment | - | - | - | 1,094 | 1,094 |
| Other cost | 0 | 0 | 0 | -17 | -17 |
| Total | 21 | 12 | 9 | 1,164 | 1,207 |
| SEK M | Americas | EMEA | APAC | Other / Group-wide |
Group total |
|---|---|---|---|---|---|
| Items affecting comparability: | |||||
| Personnel related cost | 8 | 7 | 6 | 58 | 80 |
| Depreciation and impairment | - | 0 | - | 8 | 8 |
| Other cost | - | 1 | - | 18 | 19 |
| Total | 8 | 9 | 6 | 83 | 106 |
Gross margin is used to track operational performance and efficiency and Adjusted gross margin is used to track the underlying operational performance, i.e. excluding items affecting comparability.
| Q4 | Full year | |||
|---|---|---|---|---|
| SEK M | 2024/25 | 2023/24 | 2024/25 | 2023/24 |
| Net sales | 5,156 | 5,023 | 18,016 | 18,119 |
| Cost of products sold | -3,102 | -3,194 | -11,270 | -11,342 |
| Gross income | 2,053 | 1,829 | 6,746 | 6,777 |
| Items affecting comparability | 22 | 7 | 64 | 26 |
| Adjusted gross income | 2,075 | 1,837 | 6,810 | 6,803 |
| Gross margin (Gross income/ Net sales) | 39.8% | 36.4% | 37.4% | 37.4% |
| Adjusted gross margin (Adjusted gross income/ Net sales) | 40.3% | 36.6% | 37.8% | 37.5% |
| Q4 | Full year | |||
|---|---|---|---|---|
| SEK M | 2024/25 | 2023/24 | 2024/25 | 2023/24 |
| EBITDA | 1,189 | 930 | 3,283 | 3,189 |
| Items affecting comparability | -24 | 27 | 113 | 98 |
| Adjusted EBITDA | 1,165 | 956 | 3,396 | 3,287 |
| Net Sales | 5,156 | 5,023 | 18,016 | 18,119 |
| EBITDA-margin (EBITDA/Net sales) | 23.1% | 18.5% | 18.2% | 17.6% |
| Adjusted EBITDA-margin (Adjusted EBITDA/Net sales) | 22.6% | 19.0% | 18.8% | 18.1% |
Adjusted EBIT is used to track the underlying operational performance, i.e. excluding items affecting comparability.
| SEK M | Americas | EMEA | APAC | Other / Group-wide |
Group total |
|---|---|---|---|---|---|
| Operating Income (EBIT) | 457 | 798 | 676 | -2,128 | -197 |
| Items affecting comparability | - | 6 | 0 | 1,034 | 1,040 |
| Adjusted EBIT | 457 | 804 | 676 | -1,094 | 843 |
| Q4 2023/24 | |||||
| SEK M | Americas | EMEA | APAC | Other / Group-wide |
Group total |
| Operating Income (EBIT) | 596 | 510 | 543 | -1,032 | 617 |
| Items affecting comparability | 8 | 1 | 0 | 26 | 34 |
| Adjusted EBIT | 604 | 510 | 543 | -1,006 | 651 |
| SEK M | Americas | EMEA | APAC | Other / Group-wide |
Group total |
|---|---|---|---|---|---|
| Operating Income (EBIT) | 1,946 | 2,321 | 2,224 | -5,601 | 890 |
| Items affecting comparability | 21 | 12 | 9 | 1,164 | 1,207 |
| Adjusted EBIT | 1,967 | 2,333 | 2,233 | -4,437 | 2,097 |
| Full year 2023/24 | |||||
| SEK M | Americas | EMEA | APAC | Other / Group-wide |
Group total |
| Operating Income (EBIT) | 2,070 | 2,014 | 1,834 | -3,879 | 2,039 |
| Items affecting comparability | 8 | 9 | 6 | 83 | 106 |
| Adjusted EBIT | 2,078 | 2,023 | 1,840 | -3,795 | 2,145 |
Adjusted earnings per share is used to track the underlying operational performance, i.e. excluding items affecting comparability.
| Q4 | Full year | |||
|---|---|---|---|---|
| SEK M | 2024/25 | 2023/24 | 2024/25 | 2023/24 |
| Net income for the period attributable to: | ||||
| Parent Company shareholders | -386 | 415 | 237 | 1,302 |
| Items affecting comparability | 1,040 | 34 | 1,207 | 106 |
| Tax on Items affecting comparability | -229 | - 8 |
-266 | -24 |
| Adjusted net income | 425 | 441 | 1,178 | 1,384 |
| Average number of shares, before dilution | 382 | 382 | 382 | 382 |
| Average number of shares, after dilution | 382 | 382 | 382 | 382 |
| Adjusted earnings per share before dilution 1) | 1.11 | 1.15 | 3.08 | 3.62 |
| Adjusted earnings per share after dilution 2) | 1.11 | 1.15 | 3.08 | 3.62 |
1) Adjusted net income/average number of shares before dilution 2) Adjusted net income/average number of shares after dilution
Adjusted R&D expenditure of net sales is used to track the amount spent on R&D in relation to net sales during the period, excluding items affecting comparability.
| Q4 | Full year | |||
|---|---|---|---|---|
| SEK M | 2024/25 | 2023/24 | 2024/25 | 2023/24 |
| R&D expenditure, net | 1,376 | 354 | 2,676 | 1,404 |
| R&D items affecting comparability | -962 | - 4 |
-1,023 | -10 |
| R&D capitalization | 274 | 362 | 1,207 | 1,331 |
| R&D amortization | -169 | -137 | -663 | -511 |
| Adjusted R&D Expenditure, gross | 519 | 575 | 2,197 | 2,214 |
| Net Sales | 5,156 | 5,023 | 18,016 | 18,119 |
| Adjusted R&D Expenditure of net sales | 10% | 11% | 12% | 12% |
Book-to-bill is used to measure the company's growth. A quota exceeding 1 shows that gross order intake is higher than the net sales.
| Q4 | Full year | |||
|---|---|---|---|---|
| SEK M | 2024/25 | 2023/24 | 2024/25 | 2023/24 |
| Gross order intake | 5,792 | 6,436 | 19,718 | 19,697 |
| Net sales | 5,156 | 5,023 | 18,016 | 18,119 |
| Book-to-bill | 1.12 | 1.28 | 1.09 | 1.09 |
Elekta is a global leader in radiotherapy solutions to fight cancer and neurological diseases. In fact, we are the only independent radiotherapy provider of scale. We have a broad offering of advanced solutions for delivering the most efficient radiotherapy treatments. Elekta's offering allows clinicians to treat more patients with increased quality, both with valuecreating innovations in solutions and AI-supported service based on a global network.

Elekta AB Box 7593 SE – 103 93 Stockholm, Sweden T +46 8 587 254 00 F +46 8 587 255 00

elekta.com /elekta @elekta /company/elekta @elekta_
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.